LEU— AI Stock Forecast & Price Targets
Published 8/12/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live LEU price forecast →
Centrus Energy retains a genuine structural moat as the sole U.S.-licensed HALEU enricher, reinforced by a $4.5B backlog, a $900M nondilutive DOE task order, and a fresh X-energy definitive supply contract. However, at ~$189 the stock trades at ~67x forward P/E and ~181x EV/EBITDA against negative FCF (-$53M Q2), Q2 gross margin compression to 28.3% (vs 41.1% in Q1), and 26.5% short float — a setup where the bullish catalyst cluster is largely priced in and range-top entry risk dominates. HOLD, scale in only on pullbacks toward $170-$175 support.
1-4 week view: HOLD/neutral at $189. The stock is sitting at the top of its recent range with a 1h forecast pointing to a $174-$180 pullback and the 1d directional model heavily discounted (17% accuracy vs 83% naive at 1wk horizon). Don't chase above $196; look to add on retests of $175-$180 breakout support. Hard invalidation for the intermediate uptrend is a clean break below $170 on volume, which would open $160 and potentially $145. Upside trigger is a decisive close above $200 with volume expansion — that opens $215-$225. Given 26.5% short float, expect elevated volatility both ways.
1-6 month view: Range-bound bias $170-$220 with slight upward drift as commercial HALEU narrative firms. Expected return range from $189: -10% to +16%. Key catalysts: Q3'26 gross margin print (need stabilization in high-20s to low-30s to validate operating baseline), any FY2026 guidance update, Piketon construction milestones with Geiger Brothers, cadence of X-energy prepayments and DOE task order revenue recognition. What changes the mind bullish: sustained gross margin above 30% for two consecutive quarters AND capex clarity that doesn't require equity issuance. Bearish: a construction delay/cost overrun announcement, a secondary offering, or Q3 gross margin re-compressing below 25%.
1-3 year view: The structural thesis is real — sole U.S.-licensed HALEU enricher entering a decade of policy-supported demand from SMR deployment (X-energy, Oklo, and potentially more), with multi-decade $4.5B backlog visibility and a fortress balance sheet to fund the buildout. If Piketon achieves commercial HALEU output on schedule around 2029 and margins normalize in the 25-35% range, the current 67x forward P/E can be grown into. The biggest structural risk is not demand — it's execution: enrichment facility construction historically carries significant schedule and cost overrun risk, and the market is pricing perfection. Secondary structural risk is eventual international HALEU competition (Urenco expansion is already underway) eroding the U.S. monopoly premium by the early 2030s. A 3-year fair value range of $200-$320 is defensible if commercial ramp holds; downside to $100-$130 if there is a major execution setback or capital raise.
Revenue trajectory is meaningfully improving: Q2'26 revenue of $176.1M (+14% YoY) is the second-highest quarter shown, with TTM sales at $473.9M and forward sales growth estimates just revised from -4% to +8.5%. Profitability is more mixed — Q2 net income of $16.8M (net margin 9.5%) and operating income of $10.4M (op margin 5.9%) look healthy, but gross margin compressed sharply to 28.3% from Q1's 41.1%, confirming that single-quarter margin prints are unreliable during the ramp. The balance sheet is a fortress: $1.87B cash vs $1.18B total debt (net cash ~$690M), current ratio 5.4x, working capital $1.89B — this provides real runway. But free cash flow is deeply negative: Q2 FCF -$53.2M on $71.6M capex, and capex is accelerating (Q4'25 $9.6M → Q1'26 $23.2M → Q2'26 $71.6M) as the Piketon buildout enters its capital-intensive phase. Capital allocation is disciplined — the $900M DOE task order provides nondilutive funding and X-energy prepayments further reduce equity dilution risk — but stock-based comp is a persistent drag. Valuation is the core issue: 67x forward P/E, 181x EV/EBITDA, 7.97x P/S, 4.47x P/B — priced for flawless execution of a 2029 commercial ramp.
Across timeframes the picture is a confirmed intermediate uptrend within a longer-term correction. The 1h shows the stock consolidating just below $192 after breaking out of a $170-$180 base built through late July, with actual price at $191 and the near-term forecast band pointing modestly lower toward $174-$180 — a plausible mean-reversion to the recent breakout zone. The 4h shows the broader downtrend from the $438 peak has clearly bottomed and the current advance from ~$145 is the strongest rally in months; forecast band skews slightly bullish to $224 but the model's 1wk directional accuracy (17% vs 83% naive baseline) means this must be discounted heavily. The 1d chart puts price right at the underside of the giant 2024 supply zone ($200-$250) — a well-defined resistance. RSI 57.6, price +9.2% above SMA20 and +10.4% above SMA50 but still -15.2% below SMA200, so momentum is constructive but not overbought. Key levels: support $175-$180 (recent breakout retest), then $160 and $145 (52wk low $142); resistance $196 (recent intraday high), then $200 psychological, $215-$225 (forecast band top and prior consolidation). 26.5% short float sets up squeeze risk on any positive catalyst but also crowded-long risk on any disappointment.
The signal is unambiguously bullish on catalysts: the July 1 $900M DOE HALEU task order (nondilutive, up to $1B+ with options), the August 6 definitive X-energy LEU/HALEU supply agreement (customer prepayments funding the buildout), the June Oklo LOI, S&P 600/1000/1500 index additions driving passive flows, and Q2 revenue +14% YoY with backlog to $4.5B and $3B+ in financing contingencies removed. JP Morgan raised its target to $180 but stayed Neutral — telling that even the constructive sell-side is unwilling to reach through the valuation. The noise: retail crowd is 100% bullish (a mild contrarian yellow flag), one Simply Wall St fair-value model was trimmed from $269 to $257. The one piece of real news skepticism worth carrying: StockStory flagged Q2 EPS $0.77 as 4.9% below consensus and margin pressure from ramp costs — the catalyst quality is high but execution risk on the 2029 commercial HALEU ramp is now the entire story.
- $900M DOE HALEU task order (July 2026) — nondilutive, non-debt funding to scale the sole U.S.-licensed HALEU cascade to commercial operation, with up to $170M of additional HALEU purchase options
- X-energy definitive LEU/HALEU supply agreement (Aug 2026) — customer prepayments directly fund the Piketon commercial enrichment expansion, de-risking capex
- $4.5B total backlog including $3.0B contingent enrichment backlog, with financing contingencies removed on $3B+ of contracts per Q2 disclosure
- Oklo LOI (June 2026) diversifying advanced-reactor offtake beyond X-energy
- S&P 600/1000/1500 index inclusions driving structural passive fund demand
- Geiger Brothers selected as construction contractor — buildout moving from planning into execution phase toward 2029 commercial HALEU target
- 280,000+ machine hours of successful enrichment operations since October 2023 establishing technical credibility
- Extreme valuation: ~67x forward P/E, ~181x EV/EBITDA, 7.97x P/S — priced for flawless 2029 commercial ramp with minimal cushion for missteps
- Gross margin compression to 28.3% in Q2 vs 41.1% in Q1 signals ramp-up cost pressure; margin repeatability unproven
- Accelerating capex ($9.6M → $23.2M → $71.6M over three quarters) driving Q2 FCF of -$53M, raising probability of future capital raise despite $1.87B cash
- 26.5% short float and 100% bullish retail sentiment = crowded positioning both ways, elevating volatility risk
- Range-top entry: stock has already absorbed the DOE, X-energy, Oklo, and index-inclusion catalyst cluster
- Construction/schedule risk on enrichment facility — nuclear infrastructure historically prone to cost overruns and delays
- Contingent portion of backlog depends on customer reactor deployment timelines (X-energy, Oklo) that are still early-stage
- 1wk model directional accuracy 17% vs 83% naive baseline — near-term forecasts unreliable, do not lean on them
- Future international HALEU competition (Urenco expansion) could erode monopoly premium by early 2030s
- No forward guidance provided, reducing visibility into management's own confidence on near-term trajectory
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord